U.S. Markets close in 1 hr 49 mins

Orexigen Therapeutics, Inc. (OREX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.2801-0.0099 (-0.4323%)
As of 2:02PM EDT. Market open.
People also watch
VVUSARNAKERXMNKDACHN
  • A
    Allez les bleu
    Allez les bleu
    Is OREX going to $4 before the end of the year???
  • J
    Joe
    Joe
    Good news when 3rd Q reports. Each Q going forwrd will be an improvement in earnings......

    Bipropion also helps people stop smoking and
    Nalrrexone helps with Opiod Addiction and Helps people to stop Drinking......
  • F
    Fenix I
    Fenix I
    It's a matter of time this stock heads toward north considering the huge increse in sales and market share.

    Don't sell!!!
  • E
    Edelstein
    Edelstein

    SLNO (MC $16 M) BLOCKBUSTER in Phase 3 /Rare Disease +Orphan Status /$2+ BILLION Market = REAL Unknown low float stock with 1000% upside Potential and more .Next billion dollar rare disease company like SRPT here .GLTA

    Soleno therapeutics (SLNO)

    Market Cap $16 Million
    Cash: $8 Million
    Price $0.35

    Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)

    Initiating Coverage June 26, 2017
    http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf

    •Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete

    Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.

    Market Opportunity for PWS is Substantial.

    While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
    Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.

  • J
    Jim
    Jim
    Another sham like ARNA and VVUS. Good grief...
  • O
    Ott
    Ott
    Why did I bought this #$%$ stock
  • A
    Anonymous
    Anonymous

    We must interpret a bad temper as a sign of inferiority. http://dataunion.tistory.com/9054

    Orexigen Therapeutics NASDAQ $OREX Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.5 In other words, the correlation coefficient of the other stock
    dataunion.tistory.com
  • J
    Jim
    Jim
    One positive from Contrave; it's user's can quit smoking from the buproprion and the opioid addicts can stay clean from the naltrexone.
  • F
    Fenix I
    Fenix I
    I just added more than 0,3% of orex mc to my portfolio those last days. This one is gonna rocket in a few days...

    GLTA
  • J
    Joe
    Joe
    Naltrexone ----To stop Drinking Bupropion------To stop Smoking

    And Combined, the also help people lose weight.....
  • L
    Luella
    Luella

    Did anyone else see $OREX report from http://jcharlesassets.com/heathlynked/?s=OREX ? It had some interesting information. "hhse" Making money investing.

    Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
    jcharlesassets.com
  • W
    Welch
    Welch

    Thanks for the tip, I did some research and found more information about $OREX on http://jcharlesassets.com/opiant-pharmaceuticals/?s=OREX Day trading investing. "rht"

    Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
    jcharlesassets.com
  • p
    pops or homo
    pops or homo
    this message board has dried up
  • L
    Lee
    Lee
    Excellent quarter. This sounds like a great turnaround story. We were up 18% pre-market and now only 3.8%. Even with Nasdaq down, we should be up more than this.Can't seem to shake the shorts.
  • T
    Tick tock timer
    Tick tock timer
    ha ha! YEAHHHHH! I'm long on FDBL and it has major volume today! BOOM, BOOM yha!
  • T
    Tick tock timer
    Tick tock timer
    ha ha! YEAHHHHH! I'm long on FDBL and it has major volume today! BOOM, BOOM yha!
  • T
    Tick tock timer
    Tick tock timer
    make some money on this stock and lost all most all of it on FDBL, HCMC, NEWLF and FREEF! 😢😢😢💝
  • A
    Allez les bleu
    Allez les bleu
    Agree with you not seeing commercials but how do you arrive at notion that Contrave not being prescribed by doctors?
  • L
    Lee
    Lee
    Orexigen signs a new distribution deal getting them into three major countries in Europe and the stock goes down. Tomorrow could be very ugly.
  • A
    Archibaldo
    Archibaldo
    T0pMarketGaIners.c0m is one of the best “alerts” services I have found. Just sign up and watch from the sidelines, you will see!